# Clinical Trial Landscape: 14_renal_cell_io_resistant

*Generated: 2026-01-05 07:01:23*

## Summary

- **Total Trials**: 70
- **Flagged for Review**: 0
- **Search Terms Used**: 3

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 22 | ██████ 31.4% |
| Phase 1 | 14 | ████ 20.0% |
| Unknown | 12 | ███ 17.1% |
| Not Applicable | 9 | ██ 12.9% |
| Phase 1/Phase 2 | 9 | ██ 12.9% |
| Early Phase 1 | 2 |  2.9% |
| Phase 3 | 2 |  2.9% |

## Status Distribution

- **Recruiting**: 61 (87.1%)
- **Not yet recruiting**: 8 (11.4%)
- **Enrolling by invitation**: 1 (1.4%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| National Cancer Institute (NCI) | 6 |
| M.D. Anderson Cancer Center | 3 |
| Children's Oncology Group | 2 |
| University of Alabama at Birmingham | 2 |
| City of Hope Medical Center | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns | 2 |
| Jonsson Comprehensive Cancer Center | 2 |
| Massachusetts General Hospital | 2 |
| National Institute of Diabetes and Digestive and K | 1 |
| University of Nebraska | 1 |
| Fox Chase Cancer Center | 1 |
| Mark Stein | 1 |
| Pfizer | 1 |
| University of Pennsylvania | 1 |
| Calico Life Sciences LLC | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Nivolumab | 11 |
| Computed Tomography | 8 |
| Ipilimumab | 7 |
| Biospecimen Collection | 6 |
| Questionnaire Administration | 6 |
| Cabozantinib | 5 |
| Bone Scan | 5 |
| Magnetic Resonance Imaging | 5 |
| Stereotactic Body Radiation Therapy | 3 |
| Pembrolizumab | 3 |
| Positron Emission Tomography | 3 |
| Avelumab | 2 |
| Stereotactic Ablative Radiotherapy | 2 |
| App-Based Intervention | 2 |
| Nephrectomy | 2 |
| Cemiplimab | 2 |
| Fianlimab | 2 |
| Zanzalintinib | 2 |
| [18F]-DOPA | 1 |
| Cytology Specimen Collection Procedure | 1 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 70 |
| Spain | 8 |
| Australia | 7 |
| South Korea | 7 |
| France | 7 |
| Canada | 6 |
| Japan | 5 |
| United Kingdom | 4 |
| China | 3 |
| Israel | 3 |
| Italy | 3 |
| New Zealand | 2 |
| Germany | 2 |
| Ireland | 2 |
| Chile | 2 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| renal cell carcinoma | manual | 1.0 |
| RCC | llm | 0.8 |
| clear cell renal cell carcinoma | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT07226544](https://clinicaltrials.gov/study/NCT07226544) | Phase 2 | Not yet recruiting | City of Hope Medical... | A Phase II Study of Neoadjuvant Ivo... |
| [NCT07293351](https://clinicaltrials.gov/study/NCT07293351) | Phase 1/Phase 2 | Not yet recruiting | Bristol-Myers Squibb | ROSETTA RCC-208: A Phase 1/2 Open-l... |
| [NCT07297160](https://clinicaltrials.gov/study/NCT07297160) | Phase 1 | Not yet recruiting | Baylor College of Me... | Chimeric Antigen Receptor Treatment... |
| [NCT05487859](https://clinicaltrials.gov/study/NCT05487859) | Phase 2 | Not yet recruiting | University of Alabam... | A Pilot Study of the Immunomodulato... |
| [NCT07148050](https://clinicaltrials.gov/study/NCT07148050) | Phase 1 | Recruiting | Seattle Children's H... | Immunotherapy for Solid Tumor Malig... |
| [NCT06863311](https://clinicaltrials.gov/study/NCT06863311) | Phase 2 | Recruiting | Karie Runcie | EXACT: Randomized Phase II Trial of... |
| [NCT07223541](https://clinicaltrials.gov/study/NCT07223541) | Phase 2 | Not yet recruiting | University of Oklaho... | A Randomized Phase II Trial of Cemi... |
| [NCT06138067](https://clinicaltrials.gov/study/NCT06138067) | Not Applicable | Recruiting | Sidney Kimmel Compre... | A Pilot Study of Low Versus High In... |
| [NCT07043608](https://clinicaltrials.gov/study/NCT07043608) | Phase 2 | Not yet recruiting | Kelly Fitzgerald, MD | A Phase II Study of Zanzalintinib f... |
| [NCT07124000](https://clinicaltrials.gov/study/NCT07124000) | N/A | Recruiting | AstraZeneca | Effectiveness of T-DXd Across HER2-... |
| [NCT07010978](https://clinicaltrials.gov/study/NCT07010978) | Not Applicable | Recruiting | Massachusetts Genera... | R34 Study 2 - Pilot RCT Testing the... |
| [NCT06571708](https://clinicaltrials.gov/study/NCT06571708) | Phase 2 | Recruiting | Columbia University | A Phase 2, Randomized, Open-label S... |
| [NCT07077083](https://clinicaltrials.gov/study/NCT07077083) | Phase 2 | Not yet recruiting | Massachusetts Genera... | A Pilot Study of 89Zr-girentuximab ... |
| [NCT07049926](https://clinicaltrials.gov/study/NCT07049926) | Phase 1/Phase 2 | Recruiting | Merck Sharp & Dohme ... | A Phase 1b/2 Study of Immune and Ta... |
| [NCT07046832](https://clinicaltrials.gov/study/NCT07046832) | Not Applicable | Enrolling by invitation | MediView XR, Inc. | Clinical Evaluation of an Intra-pro... |
| [NCT06401330](https://clinicaltrials.gov/study/NCT06401330) | Phase 3 | Recruiting | Children's Oncology ... | Risk Adapted Treatment of Unilatera... |
| [NCT06376669](https://clinicaltrials.gov/study/NCT06376669) | Phase 2 | Recruiting | Sidney Kimmel Compre... | Prospective Phase II Study of Stere... |
| [NCT06699602](https://clinicaltrials.gov/study/NCT06699602) | Phase 2 | Recruiting | Memorial Sloan Kette... | A Pilot Phase II Study of Neoadjuva... |
| [NCT06660654](https://clinicaltrials.gov/study/NCT06660654) | Phase 2 | Recruiting | Daiichi Sankyo | REJOICE-PanTumor01: A Phase 2, Mult... |
| [NCT06432036](https://clinicaltrials.gov/study/NCT06432036) | Phase 1/Phase 2 | Recruiting | Jonsson Comprehensiv... | RENEGADE: Radioembolization for Ear... |
| [NCT06453642](https://clinicaltrials.gov/study/NCT06453642) | Not Applicable | Recruiting | Fluidx Medical Techn... | Evaluation of a Simple-Prep Control... |
| [NCT06093568](https://clinicaltrials.gov/study/NCT06093568) | N/A | Not yet recruiting | Power Life Sciences ... | Exploring Engagement Dynamics Among... |
| [NCT06222593](https://clinicaltrials.gov/study/NCT06222593) | Phase 1/Phase 2 | Recruiting | State University of ... | A Phase I/II Study to Evaluate the ... |
| [NCT06582017](https://clinicaltrials.gov/study/NCT06582017) | Phase 1 | Recruiting | Nammi Therapeutics I... | A First-in-human Phase 1a/1b Study ... |
| [NCT04723810](https://clinicaltrials.gov/study/NCT04723810) | Phase 1/Phase 2 | Recruiting | University of Pennsy... | A Study to Evaluate the Safety and ... |
| [NCT06447103](https://clinicaltrials.gov/study/NCT06447103) | Phase 2 | Recruiting | Jonsson Comprehensiv... | 89Zr-DFO-GmAb PET/CT vs Contrast-En... |
| [NCT06161532](https://clinicaltrials.gov/study/NCT06161532) | Phase 2 | Recruiting | National Cancer Inst... | A Phase II Study of Sacituzumab Gov... |
| [NCT06399419](https://clinicaltrials.gov/study/NCT06399419) | Phase 1 | Recruiting | Osel, Inc. | An Open-Label, Phase I, Dose-Findin... |
| [NCT06265285](https://clinicaltrials.gov/study/NCT06265285) | Phase 2 | Recruiting | Mayo Clinic | Pilot Single-Arm, Pragmatic Trial o... |
| [NCT05665361](https://clinicaltrials.gov/study/NCT05665361) | Phase 1/Phase 2 | Recruiting | National Cancer Inst... | A Phase I/II Study of Palbociclib a... |
| [NCT06706765](https://clinicaltrials.gov/study/NCT06706765) | Early Phase 1 | Recruiting | University of Montan... | Group Telehealth Behavioral Cough S... |
| [NCT05410509](https://clinicaltrials.gov/study/NCT05410509) | Not Applicable | Recruiting | University of Alabam... | "Embolization Before Ablation of Re... |
| [NCT04974671](https://clinicaltrials.gov/study/NCT04974671) | Phase 2 | Recruiting | Yale University | Phase II Trial Of Stereotactic Body... |
| [NCT05931393](https://clinicaltrials.gov/study/NCT05931393) | Phase 2 | Recruiting | University of Texas ... | Phase 2, Open-label, Single Cohort,... |
| [NCT06040762](https://clinicaltrials.gov/study/NCT06040762) | Not Applicable | Recruiting | University of Washin... | The "Get Moving Trial": A Phase I/I... |
| [NCT05830058](https://clinicaltrials.gov/study/NCT05830058) | Phase 2 | Recruiting | City of Hope Medical... | Phase II Randomized Controlled Tria... |
| [NCT06108479](https://clinicaltrials.gov/study/NCT06108479) | Phase 1 | Recruiting | Dragonfly Therapeuti... | A Phase I/Ib, First-In-Human, Multi... |
| [NCT06004336](https://clinicaltrials.gov/study/NCT06004336) | Phase 2 | Recruiting | M.D. Anderson Cancer... | A Randomized Trial of Maintenance S... |
| [NCT05839119](https://clinicaltrials.gov/study/NCT05839119) | Phase 1 | Recruiting | Brown University | Targeting Androgen Signaling in Uro... |
| [NCT05928806](https://clinicaltrials.gov/study/NCT05928806) | Phase 2 | Recruiting | Michael B. Atkins, M... | Phase 2 Advanced Renal Cell Cancer ... |
| [NCT05863351](https://clinicaltrials.gov/study/NCT05863351) | Phase 3 | Recruiting | ECOG-ACRIN Cancer Re... | Phase III Randomized Trial of Stere... |
| [NCT05520099](https://clinicaltrials.gov/study/NCT05520099) | N/A | Recruiting | Elephas | Observational Basket Trial to Colle... |
| [NCT05733715](https://clinicaltrials.gov/study/NCT05733715) | Early Phase 1 | Recruiting | Abramson Cancer Cent... | Randomized Pilot Clinical Trial of ... |
| [NCT05700461](https://clinicaltrials.gov/study/NCT05700461) | Phase 1 | Recruiting | Wenxin Xu | Pilot Study of an Implantable Micro... |
| [NCT05856981](https://clinicaltrials.gov/study/NCT05856981) | Phase 1 | Recruiting | Sairopa B.V. | An Open-Label, Multicenter, Multi-a... |
| [NCT05327686](https://clinicaltrials.gov/study/NCT05327686) | Phase 2 | Recruiting | NRG Oncology | Randomized Phase II Stereotactic Ab... |
| [NCT05361720](https://clinicaltrials.gov/study/NCT05361720) | Phase 2 | Recruiting | Vanderbilt-Ingram Ca... | Optimal Treatment by Invoking Biolo... |
| [NCT05584670](https://clinicaltrials.gov/study/NCT05584670) | Phase 1/Phase 2 | Recruiting | Sanofi | A Phase 1/2, Open Label, First-in-h... |
| [NCT05048212](https://clinicaltrials.gov/study/NCT05048212) | Phase 2 | Recruiting | M.D. Anderson Cancer... | A Phase II Study of Nivolumab With ... |
| [NCT05225428](https://clinicaltrials.gov/study/NCT05225428) | Not Applicable | Recruiting | Dana-Farber Cancer I... | Video Education With Result Depende... |

*... and 20 more trials (see trials.csv for full list)*
